GlassScriptPhysician profile
Lindsay L Overko
NPI 1972648111
$29,138.36
in general payments reported to CMS, 2019-2025
18 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $279 · 2022: $714 · 2023: $1,991 · 2024: $11K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $9,798 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,370 · Travel and Lodging: $1,054 · Education: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,486.46 |
| Food and Beverage | $9,798.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,370.00 |
| Travel and Lodging | $1,054.16 |
| Education | $436.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $9,575.68 | 2022-2025 | |
| Incyte Corporation | $6,401.05 | 2023-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $3,612.34 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $2,782.34 | 2021-2025 | Dupixent |
| Janssen Biotech, INC. | $2,564.81 | 2023-2025 | Tremfya |
| Abbvie INC. | $2,278.65 | 2021-2025 | |
| Ucb, INC. | $566.94 | 2022-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $246.84 | 2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.13 | 2022-2024 | Cyltezo, Spevigo |
| Janssen Scientific Affairs, LLC | $243.83 | 2023-2025 | Tremfya |
| Sanofi-Aventis U.S. LLC | $184.99 | 2024-2025 | |
| Dermavant Sciences, INC. | $95.37 | 2023-2024 | Vtama |
| Amgen INC. | $94.46 | 2025 | |
| Lilly USA, LLC | $91.44 | 2022-2023 | Taltz |
| Galderma Laboratories, L.P. | $85.74 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $41.04 | 2023-2024 | Ilumya |
| Novartis Pharmaceuticals Corporation | $22.22 | 2022 | |
| Organon LLC | $6.49 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Overko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.